Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Biogen Halts Mid-Stage IPF Drug Trial

Days after halting Biogen’s BACE inhibitor program for Alzheimer’s disease, the Cambridge-based company stopped a clinical trial in idiopathic pulmonary fibrosis due to safety reasons.

Read More »

Arizona State University Researchers Try Novel Approach to Alzheimer’s Prevention

Researchers at Arizona State University are experimenting with a compound that might prevent Alzheimer’s and other neurodegenerative diseases, such as Parkinson’s disease, and potentially Down syndrome.

Read More »

Rutgers’ Nanotechnology Research Might Help with Alzheimer’s, Parkinson’s and Other Diseases

Researchers at Rutgers University-New Brunswick recently published research about a nanotechnology platform that helps identify what happens to specific stem cells.

Read More »

Two Genes Appear to Act as On/Off Switches for Neuroinflammation and Alzheimer’s Disease

Researchers with Massachusetts General Hospital have identified some crosstalk communication between TREM2 and CD33, two genes that play a role in inflammation and Alzheimer’s disease.

Read More »

Novartis, Amgen and Banner End Alzheimer’s Program

Novartis, Amgen and the Banner Alzheimer’s Institute announced they are halting two pivotal Phase II/III clinical trials in the Alzheimer’s Prevention Initiative Generation Program.

Read More »

Research Roundup: A New Protein Linked to Alzheimer’s and Other Highlights

Researchers at the RIKEN Center for Brain Science identified a new protein that might make the connection between amyloid plaques and tau in Alzheimer’s patients.

Read More »

Gates, Bezos team up to fund Alzheimer’s diagnostics

The Bill & Melinda Gates Foundation and Jeff Bezos’ Day One Fund teamed up to donate $15 million to the Diagnostics Accelerator as part of the Alzheimer’s Drug Discovery Foundation.

Read More »

Great-grandparents or cousins with Alzheimer’s linked to higher risk for the disease

Having second-degree or third-degree relatives with Alzheimer’s raises a person’s risk of developing the disease, a new study suggests.

Read More »

Sanofi and Denali Reach Potential $1+ Billion Deal

Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.

Read More »

Bayer, Orion drug delays spread of prostate cancer

German’s Bayer and Finland’s Orion said a study showed the prostate cancer drug darolutamide that the companies are developing can delay the spread of the disease to other body parts.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom